Last reviewed · How we verify
Moxifloxacin Injectable Product
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Used for Bacterial infections (community-acquired pneumonia, complicated skin infections, intra-abdominal infections, acute bacterial sinusitis), Hospital-acquired pneumonia, Complicated urinary tract infections.
At a glance
| Generic name | Moxifloxacin Injectable Product |
|---|---|
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Drug class | Fluoroquinolone antibiotic |
| Target | DNA gyrase; Topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Moxifloxacin binds to and inhibits DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This dual inhibition leads to rapid bactericidal activity against a broad spectrum of aerobic and anaerobic bacteria. The injectable formulation allows for systemic delivery in serious infections where oral administration is not feasible.
Approved indications
- Bacterial infections (community-acquired pneumonia, complicated skin infections, intra-abdominal infections)
- Acute bacterial sinusitis
- Acute exacerbation of chronic bronchitis
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Tendinitis/tendon rupture
- QT prolongation
- Photosensitivity
- Peripheral neuropathy
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery (PHASE4)
- Cardiac Safety Evaluation of P03277 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: